Form 4: Harvard Apparatus Regenerative Technology Director Receives Equity Compensation

Harvard Apparatus Regenerative Technology, Inc. Director Chen Jing was granted 33,817 stock options with an exercise price of $1.60 per share on June 27, 2025, as part of annual equity compensation and in lieu of cash.

Summary

• Director Chen Jing of Harvard Apparatus Regenerative Technology, Inc. (HRGN) was granted two stock option awards on June 27, 2025.
• The first award consists of 18,590 stock options, representing the annual equity grant for a non-employee director, with an exercise price of $1.60 per share and an expiration date of June 27, 2035.
• This annual equity grant will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026, and June 27, 2026.
• The second award consists of 15,227 stock options, granted in lieu of cash compensation otherwise payable to the non-employee director, also with an exercise price of $1.60 per share and an expiration date of June 27, 2035.
• The options granted in lieu of cash compensation will vest in four equal installments on the grant date (June 27, 2025), June 30, 2025, September 30, 2025, and December 31, 2025.
• Following these transactions, Director Chen Jing directly beneficially owns 33,817 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation for a non-employee director, aligning management interests with shareholders, which is generally viewed positively as a standard corporate governance practice.

Positives

• The granting of stock options to a director aligns their interests with those of shareholders, as the value of the options increases with the company's stock price.
• Utilizing equity compensation, including options granted in lieu of cash, can help conserve the company's cash reserves.

Negatives

• No negative information is disclosed in this routine insider transaction report.

Risks

• No specific risks are disclosed in this routine insider transaction report.

Future Outlook

The document details the vesting schedules for the granted stock options, indicating future dates when portions of the options will become exercisable, aligning the director's long-term interest with the company's performance.

Management Comments

• The stock options represent the annual equity grant to the Reporting Person, as a non-employee director of the Issuer.
• One stock option grant was made in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer.

Industry Context

The granting of stock options to non-employee directors is a common practice across publicly traded companies, particularly in the biotechnology and medical device sectors, to attract and retain qualified board members and align their incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The practice of compensating non-employee directors with equity, such as stock options, is a standard corporate governance practice across various industries, including life sciences and regenerative medicine.
• The vesting schedules, particularly the multi-year vesting for the annual grant, are typical for long-term incentive plans designed to encourage sustained commitment and performance.
• Granting options in lieu of cash compensation is also a recognized method for companies, especially those in growth phases, to manage cash flow while still providing competitive director remuneration.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the long-term performance of the company's stock, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• Portions of the 18,590 stock options will vest on September 27, 2025, December 27, 2025, March 27, 2026, and June 27, 2026.
• Portions of the 15,227 stock options will vest on June 30, 2025, September 30, 2025, and December 31, 2025.

Key Dates

Keywords

Harvard Apparatus Regenerative Technology, HRGN, Stock Options, Director Compensation, Equity Grant, SEC Form 4, Insider Transaction, Chen Jing, Non-Employee Director